Skip to content

McKesson MCK Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Eli Lilly logo
Eli LillyLLY
Cardinal Health logo
Cardinal HealthCAH
Cencora logo
CencoraCOR
AbbVie logo
AbbVieABBV
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$96.3B+6.0%
Gross profit$4.0B+11.1%
Operating income$2.2B+35.1%
Net income$1.7B+33.5%
EPS (diluted)$13.65+37.6%

Balance sheet

See full
Cash & equivalents$4.0B-33.3%
Total debt$2.3B-74.2%
Total equity-$2.2B-4.7%
Total assets$82.3B+9.6%

Cash flow

See full
Operating cash flow$3.4B-55.8%
CapEx$111.0M-34.3%
Free cash flow$3.3B-56.3%

Valuation

See full
Market cap$98.45B+11.6%
Enterprise value$96.75B0.0%
P/E20.7×-7.2×
P/S0.2×0.0×

Profitability

See full
Gross margin3.6%-0.1pp
Operating margin1.5%+0.3pp
Net margin1.2%+0.3pp
FCF margin1.4%-0.1pp

Returns & leverage

See full
Return on equity36%
Debt / equity
Current ratio0.9×0.0×

Where this comes from

Reported directly by McKesson in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: McKesson’s 10-K, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about McKesson's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is McKesson's deferred tax assets and other non-current assets?
McKesson (MCK) reported deferred tax assets and other non-current assets of $4.99B in Q1 2026.
How has McKesson's deferred tax assets and other non-current assets changed year-over-year?
McKesson's deferred tax assets and other non-current assets increased by 25.7% year-over-year, from $3.97B to $4.99B.
What is the long-term trend for McKesson's deferred tax assets and other non-current assets?
Over 5 years (2021 to 2026), McKesson's deferred tax assets and other non-current assets has grown at a 14.1% compound annual growth rate (CAGR), from $2.58B to $4.99B.